triazoles has been researched along with losartan potassium in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.33) | 18.7374 |
| 1990's | 1 (3.33) | 18.2507 |
| 2000's | 7 (23.33) | 29.6817 |
| 2010's | 13 (43.33) | 24.3611 |
| 2020's | 8 (26.67) | 2.80 |
| Authors | Studies |
|---|---|
| Thorling, EB | 1 |
| Cole, K; Kohn, EC; Sandeen, MA; Volpe, DA | 1 |
| Brookins, J; Fisher, JW | 1 |
| Blakey, D; Heflich, RH; Jacobs, A; Jacobsen, SD; Morita, T; Nohmi, T; O'Donovan, MR; Sasaki, YF; Sofuni, T; Tice, R; Tweats, DJ | 1 |
| Steensma, DP; Tefferi, A | 1 |
| Chaigneau, L; Demarchi, M; Lorgis, V; Maurina, T; Meaux-Ruault, N; N'guyen, T; Pivot, X; Stein, U; Thiery-Vuillemin, A; Villanueva, C | 1 |
| Ohyashiki, K | 1 |
| Brewster, UC; McPhedran, P; Yusuf, B | 1 |
| Fernández de Henestrosa, AR; García, C; Guzmán, A; Marcos, R; Marín, AP; Ruiz, MT; Tortajada, A | 1 |
| Rempe, DA; Zhao, Y | 1 |
| Chrétien, S; Fucharoen, S; Goupille, O; Granger, M; Kadri, Z; Leboulch, P; Lefèvre, C; Maouche-Chrétien, L; Penglong, T | 1 |
| Guinea de Castro, JM; Moreno de Gusmão, B; Oiartzabal, I; Perez-Persona, E | 1 |
| Tohyama, K | 1 |
| Nie, J; Wang, F; Wang, H; Zhang, C | 1 |
| Ellinghaus, P; Flamme, I; Jeske, M; Keldenich, J; Oehme, F; Thuss, U | 1 |
| Church, TJ; Frigon, NL; Lariosa-Willingham, K; Leonoudakis, D; Miller, JL; Punnonen, J; Spencer, JR; Tettenborn, CS | 1 |
| Gupta, N; Wish, JB | 1 |
| Frigon, NL; Miller, JL; Pandolfo, M; Punnonen, J; Rai, M; Spencer, JR | 1 |
| Arens, ER; Böttcher, M; Kaiser, A; Kubitza, D; Lentini, S; Thuss, U; van der Mey, D; Wensing, G | 1 |
| Gu, J; Jiang, Z; Li, Z; Wu, Y; You, Q; Zhang, X | 1 |
| Akizawa, T; Arai, M; Hirakata, H; Koretomo, R; Matsui, A; Nangaku, M; Yamaguchi, T | 1 |
| Deai, K; Fukui, K; Kobayashi, H; Matsui, T; Matsuo, A; Matsushita, M; Nangaku, M; Shinozaki, Y; Tanaka, T; Yoshiuchi, H | 1 |
| Kaiser, A; Kapsa, S; Lentini, S; Matsuno, K; van der Mey, D | 1 |
| Kittikulsuth, W; Li, L; Morisawa, N; Nakano, D; Nishiyama, A; Ohsaki, H; Suzuki, N; Yamamoto, M; Zhang, A | 1 |
| Gerisch, M; Jungmann, NA; Kaiser, A; Lentini, S; Radtke, M; Schulz, S; van der Mey, D; Yoshikawa, K | 1 |
| Fukui, K; Kobayashi, H; Matsuo, A; Matsushita, M; Shinozaki, Y; Yoshiuchi, H | 1 |
| Akizawa, T; Hayasaki, T; Hayashi, Y; Matsuda, Y; Nobori, K; Taki, K; Yamamoto, H | 1 |
| Fukui, K; Nangaku, M; Tanaka, T | 1 |
| Akizawa, T; Fujikawa, R; Fujioka, M; Nagao, Y | 1 |
| Hartner, A; Schley, G | 1 |
6 review(s) available for triazoles and losartan potassium
| Article | Year |
|---|---|
Risk-based management of myelodysplastic syndrome.
Topics: Anemia, Sideroblastic; Antilymphocyte Serum; Azacitidine; Benzoates; Decitabine; Deferasirox; DNA Modification Methylases; Enzyme Inhibitors; Erythropoietin; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Histone Deacetylase Inhibitors; Humans; Immunosuppressive Agents; Interleukin-11; Iron Chelating Agents; Lenalidomide; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Prognosis; Risk; Stem Cell Transplantation; Thalidomide; Triazoles | 2007 |
[Development trend in new therapeutic approaches for anemia].
Topics: Anemia; Benzoates; Clinical Trials as Topic; Darbepoetin alfa; Deferasirox; Erythropoietin; Hematinics; Humans; Iron Chelating Agents; Iron Overload; Lenalidomide; Myelodysplastic Syndromes; Neoplasms; Thalidomide; Triazoles | 2008 |
[Myelodysplastic syndromes: treatment strategy up-to-date].
Topics: Antilymphocyte Serum; Azacitidine; Benzoates; Cyclosporine; Cytarabine; Deferasirox; Disease Progression; Drug Discovery; Drug Therapy, Combination; Erythropoietin; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Iron Chelating Agents; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Quality of Life; Risk Assessment; Thalidomide; Triazoles | 2014 |
Protective factors in diabetic retinopathy: focus on blood-retinal barrier.
Topics: Animals; Blood-Retinal Barrier; Diabetic Retinopathy; Erythropoietin; Fenofibrate; Humans; Insulin-Like Growth Factor Binding Protein 3; Macular Edema; Protective Factors; Pyrazines; Sitagliptin Phosphate; Triazoles; Vascular Endothelial Growth Factor A | 2014 |
Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD.
Topics: Anemia; Barbiturates; Clinical Trials as Topic; Enzyme Inhibitors; Erythropoietin; Glycine; Humans; Hypoxia-Inducible Factor-Proline Dioxygenases; Isoquinolines; Pyrazoles; Renal Insufficiency, Chronic; Triazoles | 2017 |
Treatment of anemia associated with chronic kidney disease with the HIF prolyl hydroxylase inhibitor enarodustat: A review of the evidence.
Topics: Anemia; Erythropoietin; Hematinics; Humans; N-substituted Glycines; Prolyl-Hydroxylase Inhibitors; Pyridines; Renal Insufficiency, Chronic; Triazoles | 2022 |
4 trial(s) available for triazoles and losartan potassium
| Article | Year |
|---|---|
First-in-man-proof of concept study with molidustat: a novel selective oral HIF-prolyl hydroxylase inhibitor for the treatment of renal anaemia.
Topics: Administration, Oral; Adult; Anemia; Area Under Curve; Erythropoietin; Half-Life; Healthy Volunteers; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Hypoxia-Inducible Factor-Proline Dioxygenases; Male; Prolyl-Hydroxylase Inhibitors; Proof of Concept Study; Pyrazoles; Renal Insufficiency, Chronic; Single-Blind Method; Triazoles; Young Adult | 2018 |
A Placebo-Controlled, Randomized Trial of Enarodustat in Patients with Chronic Kidney Disease Followed by Long-Term Trial.
Topics: Aged; Aged, 80 and over; Anemia; Dose-Response Relationship, Drug; Double-Blind Method; Erythropoietin; Female; Ferritins; Follow-Up Studies; Hematinics; Hemoglobins; Hepcidins; Humans; Hypoxia-Inducible Factor-Proline Dioxygenases; Japan; Kidney; Male; Middle Aged; N-substituted Glycines; Placebos; Pyridines; Renal Insufficiency, Chronic; Time Factors; Treatment Outcome; Triazoles | 2019 |
Effects of oral iron and calcium supplement on the pharmacokinetics and pharmacodynamics of molidustat: an oral HIF-PH inhibitor for the treatment of renal anaemia.
Topics: Administration, Oral; Adult; Anemia; Area Under Curve; Calcium; Cross-Over Studies; Dietary Supplements; Drug Administration Schedule; Drug Interactions; Erythropoietin; Humans; Hypoxia-Inducible Factor-Proline Dioxygenases; Iron; Male; Middle Aged; Pyrazoles; Time Factors; Triazoles; Young Adult | 2020 |
Molidustat for the treatment of anemia in Japanese patients undergoing peritoneal dialysis: a single-arm, open-label, phase 3 study.
Topics: Anemia; Erythropoietin; Hematinics; Hemoglobins; Humans; Japan; Peritoneal Dialysis; Pyrazoles; Renal Dialysis; Renal Insufficiency, Chronic; Treatment Outcome; Triazoles | 2022 |
20 other study(ies) available for triazoles and losartan potassium
| Article | Year |
|---|---|
A comparison of the cobalt, methylene blue, zinc, arsenite and amino triazole effect on erythropoietin production.
Topics: Animals; Arsenic; Biological Assay; Cobalt; Erythropoietin; Female; Hypoxia; Iron; Iron Isotopes; Male; Methylene Blue; Mice; Polycythemia; Rabbits; Stimulation, Chemical; Triazoles; Zinc | 1973 |
In vitro and in vivo myelotoxicity of CAI to human and murine hematopoietic progenitor cells.
Topics: Animals; Bone Marrow Cells; Cell Division; Erythroid Precursor Cells; Erythropoietin; Granulocyte-Macrophage Colony-Stimulating Factor; Granulocytes; Hematopoietic Stem Cells; Humans; Interleukin-3; Kinetics; Leukocyte Count; Macrophages; Mice; Platelet Count; Recombinant Proteins; Spleen; Triazoles | 1995 |
Adenosine A(2A) and A(2B) receptor activation of erythropoietin production.
Topics: Adenosine; Alkaloids; Benzophenanthridines; Carcinoma, Hepatocellular; Enzyme Activation; Erythropoietin; Humans; Liver Neoplasms; Phenanthridines; Phenethylamines; Protein Kinase C; Purinergic P1 Receptor Antagonists; Pyrimidines; Receptor, Adenosine A2A; Receptor, Adenosine A2B; Receptors, Purinergic P1; RNA, Messenger; Triazoles; Tumor Cells, Cultured; Xanthines | 2001 |
Report of the IWGT working group on strategies and interpretation of regulatory in vivo tests I. Increases in micronucleated bone marrow cells in rodents that do not indicate genotoxic hazards.
Topics: Aniline Compounds; Animals; Body Temperature; Bone Marrow Cells; Erythropoietin; Guidelines as Topic; Hyperthermia, Induced; Micronucleus Tests; Mutagenicity Tests; Mutagens; Naphthoquinones; Phenol; Phenylhydrazines; Pyridines; Reserpine; Rodentia; Sensitivity and Specificity; Triazoles | 2007 |
Anticancer therapy in patients with porphyrias: evidence today.
Topics: Anastrozole; Antineoplastic Agents; Aromatase Inhibitors; Breast Neoplasms; Docetaxel; Epoetin Alfa; Erythropoietin; Female; Granulocyte Colony-Stimulating Factor; Hematinics; Humans; Letrozole; Middle Aged; Nitriles; Porphyria, Acute Intermittent; Porphyria, Variegate; Recombinant Proteins; Risk Assessment; Taxoids; Triazoles; Uterine Neoplasms | 2008 |
Hypocalcemia in a dialysis patient treated with deferasirox for iron overload.
Topics: Adult; Anemia, Sickle Cell; Benzoates; Deferasirox; Erythropoietin; Female; Humans; Hypertension; Hypocalcemia; Iron Chelating Agents; Iron Overload; Kidney Failure, Chronic; Peritoneal Dialysis; Transfusion Reaction; Triazoles | 2008 |
Formation of micronucleated erythrocytes in mouse bone-marrow under conditions of hypothermia is not associated with stimulation of erythropoiesis.
Topics: Animals; Antipsychotic Agents; Body Temperature; Bone Marrow Cells; Chlorpromazine; Erythrocytes; Erythropoiesis; Erythropoietin; Hypothermia; Hypothermia, Induced; Male; Mice; Micronuclei, Chromosome-Defective; Micronucleus Tests; Pyridines; Time Factors; Triazoles | 2008 |
Prophylactic neuroprotection against stroke: low-dose, prolonged treatment with deferoxamine or deferasirox establishes prolonged neuroprotection independent of HIF-1 function.
Topics: Animals; Astrocytes; Benzoates; Brain; Cyclic AMP Response Element-Binding Protein; Deferasirox; Deferoxamine; Erythropoietin; Extracellular Signal-Regulated MAP Kinases; Gene Deletion; Hypoxia-Inducible Factor 1; Iron Chelating Agents; Mice; Mice, Knockout; Neurons; Neuroprotective Agents; Phosphorylation; Proto-Oncogene Proteins c-akt; Stroke; Triazoles | 2011 |
BET bromodomain inhibition rescues erythropoietin differentiation of human erythroleukemia cell line UT7.
Topics: Azepines; Cell Line, Tumor; Cell Proliferation; Erythroid Cells; Erythropoiesis; Erythropoietin; Humans; Leukemia, Erythroblastic, Acute; Protein Structure, Tertiary; Proto-Oncogene Proteins c-myc; Triazoles | 2012 |
[Transfusional independence in a patient with refractory anemia with excess blasts-2 refractory to 5-azacitidine treated with deferasirox and colony stimulating factors].
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Azacitidine; Benzoates; Blood Transfusion; Chelation Therapy; Combined Modality Therapy; Deferasirox; Disease Progression; Drug Resistance; Epoetin Alfa; Erythropoietin; Fatal Outcome; Granulocyte Colony-Stimulating Factor; Humans; Iron; Iron Chelating Agents; Leukemia, Myeloid, Acute; Male; Recombinant Proteins; Triazoles | 2014 |
Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects.
Topics: Anemia; Animals; Erythropoietin; Female; Humans; Hypoxia-Inducible Factor-Proline Dioxygenases; Macaca fascicularis; Male; Pyrazoles; Rats; Rats, Wistar; Renal Insufficiency, Chronic; Triazoles; Up-Regulation | 2014 |
Discovery and Characterization of Nonpeptidyl Agonists of the Tissue-Protective Erythropoietin Receptor.
Topics: Animals; Biological Availability; Blood-Brain Barrier; Brain; Caco-2 Cells; Cells, Cultured; Cytokine Receptor Common beta Subunit; Erythropoietin; HEK293 Cells; Humans; Neurons; Pyrimidines; Rats; Receptors, Erythropoietin; Signal Transduction; Triazoles | 2015 |
Erythropoietin and small molecule agonists of the tissue-protective erythropoietin receptor increase FXN expression in neuronal cells in vitro and in Fxn-deficient KIKO mice in vivo.
Topics: Adult; Animals; Cells, Cultured; Cerebral Cortex; Erythropoietin; Female; Frataxin; Friedreich Ataxia; Histone Deacetylase Inhibitors; Humans; Iron-Binding Proteins; Leukocytes, Mononuclear; Male; Mice, Inbred C57BL; Mice, Transgenic; Middle Aged; Neurons; Neuroprotective Agents; Pyrimidines; Receptors, Erythropoietin; Recombinant Proteins; Triazoles; Young Adult | 2017 |
Click Chemistry-Based Discovery of [3-Hydroxy-5-(1 H-1,2,3-triazol-4-yl)picolinoyl]glycines as Orally Active Hypoxia-Inducing Factor Prolyl Hydroxylase Inhibitors with Favorable Safety Profiles for the Treatment of Anemia.
Topics: Administration, Oral; Anemia; Animals; Cisplatin; Click Chemistry; Erythropoietin; Female; Fluorescence Polarization; Glycine; Hemoglobins; Humans; Hypoxia-Inducible Factor-Proline Dioxygenases; Male; Mice, Inbred C57BL; Molecular Docking Simulation; Prolyl-Hydroxylase Inhibitors; Rats, Sprague-Dawley; Structure-Activity Relationship; Triazoles | 2018 |
JTZ-951 (enarodustat), a hypoxia-inducibe factor prolyl hydroxylase inhibitor, stabilizes HIF-α protein and induces erythropoiesis without effects on the function of vascular endothelial growth factor.
Topics: Animals; Basic Helix-Loop-Helix Transcription Factors; Cell Line; Dose-Response Relationship, Drug; Erythropoiesis; Erythropoietin; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Hypoxia-Inducible Factor-Proline Dioxygenases; N-substituted Glycines; Prolyl-Hydroxylase Inhibitors; Protein Stability; Pyridines; Rats; Rats, Sprague-Dawley; RNA, Messenger; Triazoles; Vascular Endothelial Growth Factor A | 2019 |
Effects of post-renal anemia treatment with the HIF-PHD inhibitor molidustat on adenine-induced renal anemia and kidney disease in mice.
Topics: Acute Kidney Injury; Adenine; Anemia; Animals; Disease Models, Animal; Erythropoietin; Hypoxia-Inducible Factor 1; Male; Mice, Inbred C57BL; Prolyl-Hydroxylase Inhibitors; Pyrazoles; Triazoles | 2020 |
Drug-drug interaction of atazanavir on UGT1A1-mediated glucuronidation of molidustat in human.
Topics: Adult; Atazanavir Sulfate; Drug Interactions; Erythropoietin; Glucuronides; Glucuronosyltransferase; Humans; Male; Middle Aged; Pyrazoles; Triazoles; Young Adult | 2021 |
JTZ-951 (enarodustat), a hypoxia-inducible factor prolyl hydroxylase inhibitor, improves iron utilization and anemia of inflammation: Comparative study against recombinant erythropoietin in rat.
Topics: Anemia, Iron-Deficiency; Animals; Arthritis, Experimental; Biomarkers; Enzyme Inhibitors; Erythrocytes; Erythropoiesis; Erythropoietin; Female; Hematinics; Hepcidins; Hypoxia-Inducible Factor-Proline Dioxygenases; Iron; N-substituted Glycines; Pyridines; Rats, Inbred Lew; Recombinant Proteins; Triazoles | 2021 |
Enarodustat to treat anemia in chronic kidney disease.
Topics: Anemia; Erythropoietin; Humans; Hypoxia-Inducible Factor-Proline Dioxygenases; N-substituted Glycines; Pyridines; Renal Insufficiency, Chronic; Triazoles | 2021 |
The prolyl hydroxylase inhibitor molidustat fails to restore erythropoietin production in the fibrotic kidney.
Topics: Erythropoietin; Humans; Hypoxia-Inducible Factor-Proline Dioxygenases; Kidney; Prolyl-Hydroxylase Inhibitors; Pyrazoles; Renal Insufficiency, Chronic; Triazoles | 2022 |